tradepost.ai Logo
Newsletter InsightsSEC AnalysisAI Top20 IndexPricing
Log in
Start free trial
tradepost.ai Logo

Empowering Traders with AI

Quick Links

Newsletter InsightsSEC AnalysisPricingFAQ

Legal

Privacy PolicyCookies PolicySecurity Disclosure PolicyTerms & ConditionsDisclaimer

Copyright © 2025 Dutchcode B.V. All rights reserved.

10-Q - Predictive Oncology Inc. (0001446159) (Filer)

Wed, May 14, 8:18 PM (39 days ago)

**Predictive Oncology Inc. (POAI) Q1 2025 Financial Summary** Predictive Oncology Inc. (POAI) reported its Q1 2025 financial results, highlighting both operational and financial challenges. The company's focus remains on applying artificial intelligence (AI) to support the discovery and development of optimal cancer therapies. **Financial Performance:** - **Revenue:** POAI reported revenue of $110,310,000, a significant increase from $4,858,000 in Q1 2024. This surge was primarily due to the completion of a tumor-specific 3D model. - **Profit Margins:** The gross profit margin improved due to increased sales of 3D models. - **Operating Expenses:** Total operating expenses decreased to $2,352,239,000 from $3,564,459,000 in Q1 2024. This reduction was driven by lower general and administrative expenses, operations, research and development expenses, and sales and marketing expenses. - **Net Loss:** The net loss for Q1 2025 was $2,442,873,000, an improvement from the $4,218,843,000 loss in Q1 2024. - **Cash Flow:** Cash and cash equivalents increased by $2,368,341,000, primarily due to proceeds from the exercise of warrants, issuance of common stock, and the sale of Eagan assets. **Operational Highlights:** - **Discontinued Operations:** POAI disposed of its Birmingham and Eagan operating segments, reclassifying them as discontinued operations. The sale of Eagan assets for $625,000, plus assumed liabilities, contributed to the improved cash flow. - **Merger Discussions:** The company discontinued discussions with Renovaro regarding a potential merger, leading to a lawsuit filed by Renovaro alleging breach of contract. - **Nasdaq Compliance:** POAI is at risk of being delisted from the Nasdaq Capital Market due to non-compliance with the minimum stockholders' equity requirement. The company is exploring options to regain compliance. **Future Outlook:** - **Funding Needs:** POAI continues to face significant funding needs to sustain operations and meet short-term obligations. The company is evaluating alternatives, including equity financing, issuing debt, and monetizing assets. - **Uncertainties:** The company faces uncertainties related to regulatory clearances, intellectual property protection, and market competition. Additionally, the ongoing lawsuit with Renovaro could impact future operations and financial condition. **Conclusion:** Predictive Oncology Inc. demonstrated improved financial metrics in Q1 2025, driven by increased revenue and reduced operating expenses. However, the company continues to face significant challenges, including funding needs, regulatory uncertainties, and potential delisting from Nasdaq. The future outlook remains uncertain, with the company exploring various financing options to sustain operations.